Previous Article | Next Article 
Journal of Virology, July 2000, p. 6324-6332, Vol. 74, No. 14
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Epstein-Barr Virus gH Is Essential for Penetration
of B Cells but Also Plays a Role in Attachment of Virus to
Epithelial Cells
Sara J.
Molesworth,
Cathleen
M.
Lake,
Corina M.
Borza,
Susan
M.
Turk, and
Lindsey M.
Hutt-Fletcher*
School of Biological Science, University of
Missouri
Kansas City, Kansas City, Missouri 64110
Received 3 February 2000/Accepted 19 April 2000
 |
ABSTRACT |
Entry of Epstein-Barr virus (EBV) into B cells is initiated by
attachment of glycoprotein gp350 to the complement receptor type 2 (CR2). A complex of three glycoproteins, gH, gL, and gp42, is
subsequently required for penetration. Gp42 binds to HLA class II,
which functions as an entry mediator or coreceptor and, by analogy with
other herpesviruses, gH is then thought to be involved virus-cell
fusion. However, entry of virus into epithelial cells is thought to be
different. It can be initiated by attachment by an unknown glycoprotein
in the absence of CR2. There is no interaction between gp42 and HLA
class II and instead a distinct complex of only the two glycoproteins
gH and gL interacts with a novel entry mediator. Again, by analogy with
other viruses gH is thought to be critical to fusion. To investigate
further the different roles of gH in infection of the two cell types
and to examine its influence on the assembly of the gH-gL-gp42 complex, we constructed two viruses, one in which the gH open reading frame was
interrupted by a cassette expressing a neomycin resistance gene and the
gene for green fluorescent protein and one as a control in which the
neighboring nonessential thymidine kinase gene was interrupted with the
same cassette. Virus lacking gH exited from cells normally, although
loss of gH resulted in rapid turnover of gL and gp42 as well. The virus
bound normally to B lymphocytes but could not infect them unless cells
and bound virus were treated with polyethylene glycol to induce fusion.
In contrast, virus that lacked the gH complex was impaired in
attachment to epithelial cells and the effects of monoclonal antibodies
to gH implied that this resulted from loss of gH rather than other
members of the complex. These results suggest a role for gH in both
attachment and penetration into epithelial cells.
 |
INTRODUCTION |
The Epstein-Barr virus (EBV) gH-gL
complex consists of three glycoproteins, gp85, the gH homolog which is
the product of the BXLF2 open reading frame (ORF) (12, 26);
gp25, the gL homolog which is the product of the BKRF2 ORF
(38); and gp42, which is the product of the BZLF2 ORF
(17). The complex behaves in many respects like its
counterparts in other herpesviruses. Glycoprotein gH is dependent on gL
for authentic processing and transport (38), and the complex
as a whole has been implicated as important to the ability of virus to
fuse with the cell membrane and penetrate into the cytoplasm (11,
22). The precise roles of the individual members of the complex
are, however, still being elucidated and appear to depend in part on
the cell type that the virus is infecting.
Infection of the B lymphocyte is dependent on an interaction between
gp42 and HLA class II (32) which functions as an entry mediator for this cell type (16). A monoclonal antibody
(MAb) to gp42 that blocks binding to HLA class II blocks virus-cell fusion (22), B cells that lack class II cannot be
superinfected unless class II expression is restored (16),
and a virus that lacks gp42 is unable to infect B cells unless a
soluble form of gp42 that reassociates with the gH-gL complex is
supplied in trans (36). These experiments have
been interpreted to mean that following attachment of the virus
glycoprotein gp350/220 (24, 34) to its primary B
cell receptor, the complement receptor type 2 (CR2) (6, 25),
gp42 binds to HLA class II (16). By analogy with other
herpesviruses, the next step in virus entry is thought to involve a
critical role for gH in the fusion process. However, no MAbs that react
with gH and neutralize B-cell infection have yet been found, and thus
there is currently no direct evidence for the involvement of gH in
B-cell infection.
Infection of the epithelial cell is different in several important
respects. First, although it may be initiated by attachment of virus to
CR2 (5, 18), there is also evidence for CR2-independent attachment mediated by an as-yet-unknown EBV glycoprotein (15, 39). Second, the roles played by the members of the gH complex are different. Although supply of soluble gp42 in trans to
wild-type virus or, in larger amounts, to virus deleted for expression
of gp42 can inhibit infection as well or better than it can inhibit infection of B cells, the native glycoprotein is dispensable for infection of epithelial cells (37). In addition, MAbs that
react with gH and which have no effect on B-cell transformation are capable of neutralizing infection of epithelial cells (17). These experiments were initially done with an epithelial cell line
called SVKCR2 to which virus binds via an interaction between gp350 and
CR2 and have been repeated with cell lines that lack CR2. They have
been interpreted to mean that following attachment of virus to a
primary receptor, gH interacts with a novel coreceptor or entry
mediator via a domain that can be blocked by at least some neutralizing
MAbs to gH or by the addition of gp42 to the gH-gL complex. Analysis of
the gH-gL-gp42 complex in wild-type virus has indicated the presence of
more gH and gL than gp42, further supporting a hypothesis in which
virus maintains both a three-part complex that is required to infect B
cells and a two-part complex, lacking gp42, that is required to infect
epithelial cells (37). Analysis of virus lacking gp42 also
reveals that gH and gL alone can form a detergent-stable complex
(36). The effects of the loss of gH are, however, less
certain. Velocity sedimentation analysis of the preformed complex has
suggested that there may be an interaction between gp42 and gL
(17), but it has not proven possible to demonstrate such an
interaction in a transient-expression system.
Two types of recombinant virus were made in order to answer some of
these questions that remain about the role of gH in assembly and
function of the gH-gL-gp42 complex, one in which the BXLF2 ORF was
disrupted and one in which the nonessential thymidine kinase encoded by
the BXLF1 ORF was disrupted. In both viruses a cassette expressing
neomycin resistance and a modified green fluorescence protein (GFP) was
used for the disruption to facilitate identification of successfully
penetrated cells. We report here that virus lacking gH also fails to
express detectable amounts of gL and gp42. Not only does it fail to
penetrate B cells but it is also impaired in attachment to CR2 negative
epithelial cells.
 |
MATERIALS AND METHODS |
Cells.
Akata, a Burkitt lymphoma-derived cell line that
carries EBV and can be induced to make virus (33) (a gift of
John Sixbey, St. Jude Children's Research Hospital, Memphis, Tenn.)
and EBV-negative Akata cells (a gift of Jeffrey Sample, St. Jude
Children's Research Hospital) were grown in RPMI 1640 (Sigma Chemical
Co., St. Louis, Mo.) supplemented with 10% heat-inactivated fetal
bovine serum (Gibco-BRL Life Technologies, Grand Island, N.Y.). AGS
cells (a gift of Shosuke Imai, Hokkaido University School of Medicine, Sapporo, Japan) were grown in Ham F-12 nutrient mixture (Gibco-BRL) supplemented with 10% heat inactivated fetal bovine serum. SVKCR2 cells (18) (a gift of A. B. Rickinson, University of
Birmingham, Birmingham, England) were grown in Joklik modified Dulbecco
modified Eagle medium supplemented with 10% heat-inactivated fetal
bovine serum (HyClone, Logan, Utah) and 10 ng of cholera toxin (Sigma) per ml. Human leukocytes were obtained from heparinized adult peripheral blood by flotation on lymphocyte separation medium and
depleted of T cells by a double cycle of rosetting with sheep erythrocytes as previously described (17).
Virus production.
EBV was obtained from the clarified
culture medium of Akata cells that had been resuspended at a
concentration of 4 × 106 per ml and induced with 50 µg of anti-human immunoglobulin G per ml for 5 days. Virus was either
harvested under sterile conditions, passed through a 0.8-µm
(pore-size) filter and used directly or else concentrated by high-speed
centrifugation, resuspended in fresh medium, and sterilized by passing
through a 0.45-µm (pore-size) filter.
Antibodies.
MAbs 72A1 reacting with gp350 (13),
E2A5 reacting with gp78 (20), F-2-1 reacting with gp42
(17), and E1D1 (26), CL59, and CL40 reacting with
gH were obtained from spent culture medium of hybridoma cells grown in
RPMI 1640 supplemented with 20% heat-inactivated fetal bovine serum.
MAb F-2-1 is of the immunoglobulin G2a subclass. All the other MAbs are
of the immunoglobulin G1 subclass. MAbs E1D1, CL59, and CL40 all
recognize different epitopes on gH. MAb CL59 reacts equally well in
indirect immunofluorescence assays with recombinant gH expressed alone
or gH expressed in combination with gL, whereas MAb CL40 reacts
strongly with gH expressed in combination with gL and only weakly with
gH expressed alone (data not shown). MAb E1D1 only reacts with gH that
is coexpressed with gL in mammalian cells (17), but it does
react with a truncated form of gH expressed in insect cells, confirming
that the epitope it recognizes is present on gH. An antipeptide
antibody (anti-gL) was made to a synthetic peptide corresponding to
residues 125 to 137 of gL (38). All antibodies were purified
by chromatography on protein A (Sigma) coupled to Affigel-15 (Bio-Rad,
Richmond, Calif.).
Radiolabeling and immunoprecipitation.
EBV proteins were
labeled biosynthetically with [3H]glucosamine (20 Ci/mmol; Amersham Corp., Arlington Heights, Ill.) for 20 h at
6 h after induction with anti-human immunoglobulin G as previously described (38). Labeled cells were solubilized in
radioimmunoprecipitation buffer (50 mM Tris-HCl, pH 7.2; 0.15 M NaCl;
1% sodium deoxycholate; 0.1% sodium dodecyl sulfate [SDS]; 0.1 mM
phenylmethylsulfonyl fluoride; 100 U of aprotinin per ml) and
immunoprecipitated with antibody and protein A-Sepharose CL4B (Sigma).
Immunoprecipitated proteins were washed, dissociated by boiling in
sample buffer containing 2-mercaptoethanol, and analyzed by
SDS-polyacrylamide gel electrophoresis in 10% acrylamide cross-linked
with 0.28% N,N'-diallyltartardiamide, followed
by fluorography.
Derivation of viruses in which either the BXLF2 ORF or BXLF1 ORF
is disrupted.
Dextran-purified virus harvested from the spent
medium of 8 × 109 Akata cells was digested with
proteinase K, and virion DNA was purified three times by centrifugation
in cesium chloride. DNA that sedimented at a density of 1.718 g of
cesium per ml was digested with HindIII. The 6-kb F
fragment which corresponded to bp 140893 to 146916 of the B95-8
sequence (2) was cloned into pGEM (Promega) that had been
modified to remove the HincII site in the multiple cloning
site. A 3,223-bp SmaI fragment containing the neomycin resistance gene under control of a thymidine kinase promoter and a
modified GFP gene under control of the cytomegalovirus promoter (UF5)
was excised from plasmid pTR-UF5 (received from Nicholas Muzyczka,
University of Florida, Gainesville, Fla.) which had been derived from
pTRBS-UF3 (40). It was cloned either into a
unique EcoRV site at bp 142763, 273 bp from the initiation
codon of the BXLF2 ORF, or into a unique HincII site at bp
143466, 1,395 bp from the initiation codon of the BXLF1 ORF (Fig.
1). The HindIII F
fragments, now 9.2 kb as a result of the insertions, were purified and
used to transfect Akata cells using DEAE-dextran as described previously (36). Cells were then plated at 104
cells per well in 96-well tissue culture plates in medium containing 700 µg (500 µg active) per ml of G418 (Gibco-BRL/Life Technologies, Grand Island, N.Y.) and fed weekly with fresh drug-containing medium.
Resistant clones began to emerge after approximately 3 weeks.
Drug-resistant Akata cells were screened by Southern blotting for the
presence of homologous or illegitimate recombination with cellular or
viral DNA. To eliminate wild-type episomes in cells that screened
positive for homologous recombination, virus was induced and rescued at
a low multiplicity into EBV-negative Akata cells which were reselected
with G418 (4).

View larger version (38K):
[in this window]
[in a new window]
|
FIG. 1.
Southern blot analysis of DNA from cells harboring
wild-type virus (Wt), a mixture of wild type and recombinant virus
(Wt+Rc), or pure recombinant virus (Rc). The diagrams above the blots
show the strategy for insertion of the UF5 cassette; the diagrams below
the blots show the fragments expected with the indicated probe. (A) DNA
from virus with the UF5 cassette inserted into the BXLF2 ORF, digested
with XbaI, and probed with the HindIII F
fragment. (B) DNA from virus with the UF5 cassette inserted into the
BXLF1 ORF, digested with XhoI, and probed with the
HindIII F fragment. The numbering of the base pairs
corresponds to the B95-8 sequence except in panel A. B95-8 virus has a
11,801-bp deletion that begins at bp 152012 (2). The
XbaI site at position 152912 was therefore predicted from
the sequence of this deletion in the Raji strain of virus
(28). Sizes in kilobases are indicated by horizontal
arrows.
|
|
Southern blotting.
Cells were digested overnight at 56°C
with proteinase K (1 mg/ml in 100 mM NaCl-10 mM Tris-HCl (pH 8.0)-25
mM EDTA-0.5% SDS), and DNA was purified by phenol-chloroform
extraction and ethanol precipitation. Purified DNA was digested
overnight with XbaI to identify insertion into the BXLF2 ORF
and with XhoI to identify insertion into the BXLF1 ORF. DNA
was separated by agarose gel electrophoresis in 0.7% agarose,
transferred to a nylon membrane (Magnacharge), and cross-linked and
hybridized with the 6-kb HindIII F fragment which had
been labeled with 32P.
Slot blot assays.
The amount of EBV DNA in cells or virion
particles was measured by hybridization with the BamHI W
fragment of EBV DNA labeled with 32P as previously
described (36) and quantified by scanning with a Molecular
Dynamics Storm PhosphorImager.
Flow cytometric analysis of virus binding and entry.
To
examine virus binding, cells were fixed in ice-cold 0.1%
paraformaldehyde and incubated with virus for 1 h on ice. Binding was visualized with MAb 72A1 to gp350 and sheep anti-mouse
immunoglobulin coupled to fluorescein isothiocyanate (ICN Biomedical,
Inc., Costa Mesa, Calif.). Cells incubated with both antibodies but no
virus were used as controls. Infection of cells with virus expressing GFP was measured directly by flow-cytometric analysis of unfixed cells.
Infection of EBV-negative Akata cells was analyzed 72 h after
infection, and infection of AGS cells was analyzed at 5 days postinfection.
Gardella gel analysis of virus binding.
Two million Akata
cells or 106 AGS cells were incubated with virus for 1 to
2 h on ice, after which cells were washed repeatedly with medium.
Cells were pelleted at 325 × g for 4 min and
resuspended in 40 µl of buffer containing 90 mM Tris-borate, 2 mM
EDTA, 20% Ficoll 400, and 0.01% bromophenol blue. Each sample was
then transferred to the well of a Gardella gel (8) for
analysis of the amount of virion DNA bound to cells. Gels were run as
described earlier (14), depurinated, alkalinized, and
neutralized before transfer to a Nytran membrane (Schleicher and
Schuell, Inc., Keene, N.H.). EBV DNA was visualized by probing with a
BamHI W fragment of EBV DNA labeled with 32P as
described above. In experiments with MAbs, virus and MAbs were
preincubated for 1 h at 37°C.
Assays for infection.
Five million T-cell-depleted
peripheral blood leukocytes were incubated at 37°C with 300 µl of
dilutions of filtered culture supernatant from induced Akata cells.
After 2 h, the volume was brought to 5 ml with medium containing
serum and the cells were reincubated. A total of 5 × 105 EBV-negative Akata cells were incubated with 150 µl
of virus for 2 h at 37°C, after which the volume was brought to
3 ml and the cells were reincubated. AGS cells and SVKCR2 cells were
plated in six-well tissue culture dishes grown to 80 to 90%
confluency. Then, 600 µl of virus was added to the cells for 4 h, followed by approximately 2.5 ml of medium. Five days later both
leukocytes and Akata cells were harvested and analyzed for expression
of EBNA-1 by Western blotting. In addition, 6 × 105
T-cell-depleted peripheral blood leukocytes were incubated for 1 h
at 37°C with 240 µl of virus, plated in quintuplicate at
105 cells per well in 96-well tissue culture plates and
reincubated for 4 weeks, at which time wells were examined for the
presence of transforming foci.
Polyethylene glycol-mediated infection.
Samples of 5 × 106 T-cell-depleted peripheral blood leukocytes were
incubated for 2 h on ice with wild-type or recombinant virus or
growth medium. Cells were washed once and gently resuspended in 1 ml of
35% polyethylene glycol 1500 (Boehringer Mannheim) or serum-free
medium for 5 min. Then, 10 ml of medium was added, cells were
centrifuged at 400 × g, washed, resuspended in fresh growth medium, and incubated for 14 days before harvesting and Western
blot analysis.
Western blotting.
Proteins were electrophoresed in
polyacrylamide and then electrically transferred onto nitrocellulose
membranes (0.45-µm pore size; Schleicher and Schuell) at 125 mA for
6 h. The transferred sheets were reacted overnight with blocking
buffer (10 mM Tris-HCl, pH 7.2; 0.15 M NaCl; 5% skim milk; 0.05%
sodium azide) containing a 1/500 dilution of EBNA-1-positive human
serum. They were then washed five times with wash buffer (10 mM
Tris-HCl, pH 7.2; 0.15% NaCl; 0.3% Tween 20) for 10 min each time.
The washed sheets were reacted with alkaline phosphatase-conjugated
goat anti-human antibodies (HyClone) for 2.5 h, and the bound
anti-human antibodies were detected by reacting with substrate
5-bromo-4-chloro-3-indolylphosphate and Nitro Blue Tetrazolium (Sigma).
 |
RESULTS |
Generation of recombinant viruses with the BXLF1 or BXLF2
ORFs disrupted by UF5.
An Akata HindIII F fragment
into which the UF5 cassette had been inserted either into the BXLF1 or
the BXLF2 ORF was transfected into Akata cells carrying EBV episomes,
and cells in which recombination had occurred were obtained by
selection in the presence of G418. Clones in which homologous as
opposed to illegitimate recombination had occurred were identified by
Southern blotting (Fig. 1). To derive cells that contained only
recombinant episomes in the absence of wild-type episomes, cells from
each were induced with anti-human immunoglobulin, and virus harvested
from the spent culture medium was used to infect EBV-negative Akata
cells. Drug-resistant clones that grew out after infection with virus
from each parental clone were tested for the ability to be induced to
make virus and for the presence of recombinant but not wild-type
episomes (e.g., Fig. 1). One inducible clone from each of two
independently isolated parents was selected for further study. The
phenotype of recombinant virus with UF5 inserted into the BXLF1 ORF
(Rc-TK) was, as expected (31), indistinguishable from that
of wild-type virus (data not shown). Both recombinants with UF5
inserted into the BXLF2 ORF (Rc-gH) had the same phenotype, which was
defective in several respects relative to wild-type virus. These
defects are described in detail below. GFP was expressed in all cells
harboring virus carrying the UF5 cassette.
Disruption of the BXLF2 ORF affects expression of the entire
gH-gL-gp42 complex.
To examine the effect of disrupting the BXLF2
ORF on the expression of the gH-gL-gp42 complex, cells carrying Rc-gH,
Rc-TK, or wild-type virus were induced with anti-human immunoglobulin, labeled with [3H]glucosamine, and immunoprecipitated with
MAb E2A5 against gp78, MAb F-2-1 against gp42, MAb CL59 against gH, or
anti-gL, an antibody made to a peptide derived from the predicted gL
sequence. No detectable gH could be immunoprecipitated from Rc-gH virus
(Fig. 2). In addition, antibodies to gL
and gp42 were unable to specifically immunoprecipitate their respective
targets. The amounts of radioactivity immunoprecipitated from cells
harboring wild-type and recombinant viruses by antibody to gp78, a
glycoprotein encoded by the BILF2 ORF (20), were 166,720 and
39,460 cpm, respectively, indicating that induction and labeling of
wild-type virus proteins was better than for recombinant proteins.
However, repeated experiments and longer exposures of autoradiographs
confirmed that the Rc-gH virus was deficient in all three components of
the gH-gL-gp42 complex. No defects in expression of the gH complex were
seen in the Rc-TK virus.

View larger version (58K):
[in this window]
[in a new window]
|
FIG. 2.
Electrophoretic analysis of proteins immunoprecipitated
by MAb E2A5 to gp78, MAb F-2-1 to gp42, MAb CL59 to gH, or rabbit
anti-peptide antibodies to gL from Akata cells harboring wild-type
episomes or episomes in which the UF5 cassette was inserted into the
BXLF2 (Rc-gH) or the BXLF1 (Rc-TK) ORFs. The cells were induced with
anti-human immunoglobulin and labeled with
[3H]glucosamine. Numbers at the left indicate the sizes
in kilodaltons.
|
|
Virus lacking gH exit cells normally.
To examine whether the
loss of the gH complex in the Rc-gH virus influenced its ability to
egress from cells, a cell blot assay was used to assess the total
amount of virion DNA associated with induced cells and the
DNase-resistant, encapsidated DNA that could be pelleted from spent
culture medium after it had been filtered through a 1.2-µm-pore-size
filter to remove cells. A comparison of the ratios of the two for two
Rc-gH clones and for wild-type virus showed that, although they varied
from induction to induction, there was no evidence that cells harboring
recombinant virus consistently released more or less encapsidated
virion DNA than did those harboring wild-type virus (Table
1).
View this table:
[in this window]
[in a new window]
|
TABLE 1.
Comparison of the efficiency of egress of wild-type virus
and two independently isolated recombinant viruses that lack gH
|
|
Virus lacking gH binds normally to B cells but is impaired in
binding to epithelial cells.
Binding of virus to B cells
(EBV-negative Akata cells) and AGS cells was examined by flow cytometry
using viruses that had been equilibrated by slot blot analysis for
virus DNA content. No differences in the binding of wild-type virus,
Rc-TK, and two independently isolated Rc-gH viruses could be detected
(Fig. 3, top panel). However, both Rc-gH
viruses were significantly impaired in their ability to bind to AGS
cells (Fig. 3, bottom panel). To determine whether the small amount of
residual binding represented low-level expression of CR2 which has been
reported for some epithelial cell lines (5), virus was
preincubated with MAb 72A1, which blocks virus binding to CR2 (13,
22) before addition to AGS cells or EBV-negative Akata cells
which express CR2. Binding to AGS cells was very slightly increased by
MAb 72A1 although, despite the fact that large amounts of virus were
used to provide a strong signal in the flow cytometer, it significantly
reduced virus binding to the EBV-negative Akata cells (Fig.
4).

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 3.
Flow cytometric analysis of binding of equal amounts of
wild-type, Rc-TK, or Rc-gH virus to EBV-negative Akata cells (top
panel) or AGS cells (bottom panel). In the top panel, arrow 1 indicates
the histogram of cells incubated with MAb 72A1 to gp350 and
fluorescein-conjugated sheep anti-mouse immunoglobulin alone; all
remaining histograms represent cells incubated with wild-type, Rc-TK,
or two independent isolates of Rc-gH virus. In the bottom panel, arrow
1 indicates the histogram of cells incubated with MAb 72A1 to gp350 and
fluorescein-conjugated sheep anti-mouse immunoglobulin alone; arrow 2 indicates two histograms representing cells incubated with two
independent isolates of Rc-gH; arrow 3 indicates two histograms
representing cells incubated with wild-type virus and Rc-TK.
|
|

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 4.
Flow-cytometric analysis of the effects of MAb 72A1 to
gp350 on virus binding to AGS cells (A and B) or EBV-negative Akata
cells (C). The virus used in panels A and C is Rc-TK; the virus used in
panel B is Rc-gH. In each panel arrow 1 indicates the histogram of
cells incubated with MAb 72A1 to gp350 and fluorescein-conjugated sheep
anti-mouse immunoglobulin alone; arrow 2 indicates the virus bound
after preincubation with phosphate-buffered saline and visualized with
MAb 72A1 and fluorescein-conjugated sheep anti-mouse immunoglobulin;
arrow 3 indicates the virus bound after preincubation with MAb 72A1 and
visualized with MAb 72A1 and fluorescein-conjugated sheep anti-mouse
immunoglobulin.
|
|
Since gH appeared to play a major role in attachment of virus to AGS
cells, the effects of the three MAbs to gH that neutralized infection
of AGS cells were also studied further. We have previously reported on
the biological effects of one of these antibodies to gH, MAb E1D1. This
antibody has no effect on B-cell infection, but it inhibits infection
of SVKCR2 cells. Virus binds to SVKCR2 cells via an interaction between
gp350 and CR2, and thus neutralization is not mediated by inhibition of
binding to a primary receptor. Rather, it has been hypothesized that
MAb E1D1 blocks the interaction of gH with a novel epithelial cell
coreceptor or entry mediator (37). Two newer anti-gH
antibodies, MAbs CL59 and CL40 behaved in the same way as MAb E1D1.
Both antibodies neutralized virus infection of AGS cells and SVKCR2
cells but did not inhibit infection of EBV-negative Akata cells,
although a control MAb F-2-1 to gp42 did so quite efficiently (Fig.
5). As previously shown, MAb 72A1 to
gp350 could neutralize infection of both SVKCR2 cells and EBV-negative Akata cells. However, as expected from the flow cytometry experiments shown in Fig. 4, it was not able to neutralize infection of AGS cells.
The effects of MAbs E1D1, CL40, and CL59 on virus binding to AGS cells
were then also examined by flow cytometry. Neither MAb CL40 nor MAb
CL59 inhibited virus binding, as judged by this assay, instead both
MAbs, particularly MAb CL59, appeared to increase virus binding by a
small amount (Fig. 6). However, in contrast, virus binding to AGS cells
was reduced by MAb E1D1.

View larger version (55K):
[in this window]
[in a new window]
|
FIG. 5.
Western blot analysis of induction of EBNA-1 in SVKCR2
cells, AGS cells, and EBV-negative Akata cells by virus preincubated
with growth medium or with MAbs 72A1 to gp350, E1D1, CL59 and CL40 to
gH, or F-2-1 to gp42, as indicated. Blots were reacted with human serum
containing antibodies to EBNA-1 and with goat anti-human immunoglobulin
conjugated to alkaline phosphatase. Uninduced Akata cells were included
on the far left of the top blot to demonstrate the electrophoretic
mobility of EBNA-1 in this strain of virus. The virus used in the
leftmost panel of EBV-negative Akata cells was virus released into the
supernatant of virus-producing cells. The virus used in the other
panels was concentrated 30-fold from this supernatant by
centrifugation.
|
|
The slight increase in virus binding to AGS cells measured by flow
cytometry after preincubation with either MAb 72A1 (Fig. 4A and B) or
CL59 and CL40 (Fig. 6A and B) might have
reflected an increase in MAb bound to virus that was available for
detection by the fluorescein-conjugated sheep anti-mouse immunoglobulin used for detection. Both 72A1 and CL59 provide very strong fluorescence signals when reacted with virus alone. Virus binding assays were therefore repeated using Gardella gels to analyze the amount of virus
DNA that associated with each cell type. Virus was preincubated with
medium or antibody before incubation with EBV-negative Akata cells or
AGS cells that had been briefly fixed in ice-cold paraformaldehyde. Excess virus was removed by washing, and the cells were lysed and
digested in the wells of a Gardella gel. Linear virion DNA was run into
the gel, Southern blotted, and probed. MAb 72A1 to gp350 blocked virus
binding to EBV-negative Akata cells but not to AGS cells. MAb CL59 had
little effect on binding to either cell type (Fig.
7). In contrast, although MAb E1D1 had no
effect on virus binding to EBV-negative Akata cells, it did reduce
virus binding to AGS cells, a finding consistent with the effects
measured by flow cytometry. If the Southern blots of the AGS binding
assay were scanned at low exposure with a Molecular Dynamics Storm
PhosphorImager, the percent virus binding in the presence of the
antibodies relative to binding in the presence of medium alone was
118% for MAb 72A1, 77% for MAb CL59, and 35% for MAb E1D1.

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 6.
Flow-cytometric analysis of the effects of MAbs CL40
(A), CL59 (B), and E1D1 (C) on binding of wild-type Akata virus to AGS
cells. In each panel arrow 1 indicates the histogram of cells incubated
with MAb to 72A1 to gp350 and fluorescein-conjugated sheep anti-mouse
immunoglobulin alone; arrow 2 indicates the virus bound after
preincubation with phosphate-buffered saline and visualized with MAb
72A1 and fluorescein-conjugated sheep anti-mouse immunoglobulin; arrow
3 indicates the virus bound after preincubation with MAb C140, CL59, or
E1D1 and visualized with MAb to 72A1 and fluorescein-conjugated sheep
anti-mouse immunoglobulin.
|
|

View larger version (50K):
[in this window]
[in a new window]
|
FIG. 7.
Southern blot of Gardella gel analyses of the amounts of
Akata virus bound to EBV-negative Akata (top panel) or AGS cells
(bottom panel) in the presence of growth medium, MAb 72A1 to gp350, or
MAbs CL59 and E1D1 to gH.
|
|
Virus lacking gH cannot penetrate cells but can be rescued by the
exogenous fusogen polyethylene glycol.
Since Rc-gH viruses were
apparently unimpaired in their ability to bind to B cells, they were
tested for their ability to penetrate and infect. The failure of virus
to bind to AGS cells and the concomitant failure of virus to infect AGS
cells, as judged by the most sensitive measure of expression of GFP
(data not shown), prohibited examination of whether virus was also
impaired in the penetration of epithelial cells with this cell type.
However, the stable expression of CR2 by the SVKCR2 cell line provided a surrogate experimental model. When equal amounts of Rc-gH and Rc-TK
viruses were added to EBV-negative Akata cells or SVKCR2 cells, only
the Rc-TK virus induced expression of EBNA-1 (Fig. 8). In addition, only Rc-TK induced the
expression of GFP in Akata cells (Fig. 8B). Wild-type virus exhibited
transforming activity over the entire range of dilutions tested from
1/5 to 1/2,000, whereas over the same range of dilutions the virus that
lacked gH had no detectable transforming activity. To determine whether this defect was restricted to virus penetration, freshly isolated B
cells were incubated with Rc-gH virus or a virus that lacks gp42 and
has been previously shown to be defective in penetration (36) and treated with the exogenous fusogen polyethylene
glycol. Both viruses induced EBNA-1 in these cells in the presence, but not the absence, of polyethylene glycol (Fig.
9).


View larger version (52K):
[in this window]
[in a new window]
|
FIG. 8.
(A) Western blot analysis of the ability of equal
amounts of Rc-TK and Rc-gH viruses to induce EBNA-1 in EBV-negative
Akata cells (left panel) or SVKCR2 cells (right panel). Blots were
reacted with human serum containing antibodies to EBNA-1 and with goat
anti-human immunoglobulin conjugated to alkaline phosphatase. (B)
Flow-cytometric analysis of the ability of equal amounts of Rc-TK and
Rc-gH viruses to infect and express GFP in EBV-negative Akata cells.
Cells were analyzed 72 h after infection. Arrow 1 indicates the
histogram of uninfected cells; arrow 2 indicates the histogram of cells
infected with Rc-gH virus; arrow 3 indicates the histogram of cells
infected with Rc-TK. The increase in cells in the right tail of the
uninfected cell profile after infection with either Rc-gH or Rc-TK
represents an increase in dead cells which can be seen by fluorescent
microscopy to become slightly yellow.
|
|

View larger version (33K):
[in this window]
[in a new window]
|
FIG. 9.
Western blot analysis of T-cell-depleted leukocytes
infected with Rc-gH or a recombinant virus lacking gp42, the product of
the BZLF2 ORF (36) (Rc-gp42) in the presence or absence of
polyethylene glycol. Blots were reacted with human serum containing
antibodies to EBNA-1 and with goat anti-human immunoglobulin conjugated
to alkaline phosphatase.
|
|
 |
DISCUSSION |
Essentially all of the gH homologs that have been studied to date
in many different herpesviruses have been implicated as playing a role
in virus penetration, and null mutants have been made to confirm this
role in herpes simplex virus (7), pseudorabies virus
(1, 29), and bovine herpesvirus 1 (21, 30). The evidence for involvement of the EBV gH in penetration has been indirect. Removal of the entire gH-gL-gp42 complex from virosomes made
from EBV proteins resulted in vesicles that retained the ability to
bind to receptor-positive B cells but not to fuse (11), but
no antibodies to gH have been identified that block entry into B cells.
The current study was in part an attempt to address the question
directly by construction of an EBV recombinant that lacks gH. The
results reported here are consistent with a role for gH in penetration
into B cells but retain some ambiguity, since the loss of gH apparently
resulted in a rapid turnover of gL and gp42 as well. Thus, while it
seems extremely unlikely that either gL or gp42 are central to
virus-cell fusion, since both are type 2 membrane proteins with
sequences that are not predicted to be particularly hydrophobic, the
possibility cannot be completely ruled out, and the complex is still
probably best considered the functional unit.
More enlightening and surprising were the observations made with the
epithelial cell line AGS. Binding of B cells by virus lacking gH was
unimpaired. This was expected since the glycoprotein gp350 has a very
high affinity for its B-cell receptor CR2 (23). However, it
is clear that gH plays a major role in attachment of virus to
epithelial cells such as the AGS line which can be infected in a
CR2-independent manner (15, 39). Our own unpublished observations confirm that expression of CR2 cannot be detected on these
cells by indirect immunofluorescence with appropriate MAbs or by
reverse transcription and PCR. In addition, as shown here, virus
binding is unaffected by MAb 72A1, which binds to gp350 and efficiently
inhibits attachment to CR2. The recombinant virus that lacks gH was,
however, almost completely unable to bind to AGS cells and was also
unable to infect them.
Two issues are immediately raised by this finding. The first issue is
whether or not it is gH or another member of the complex that mediates
binding to epithelial cells. Since a recombinant virus that lacks gp42
(36) can infect AGS cells in a CR2-independent manner (data
not shown), the choices are between gH and gL. The most straightforward
explanation of the ability of MAb E1D1 and perhaps to a lesser extent
MAb CL59 to inhibit virus binding would suggest that it is gH itself
that functions in attachment. The second issue relates to the identity
of the molecule(s) with which gH is interacting on AGS cells. Previous
work with the SVKCR2 cell line had already suggested that gH interacted
with a novel epithelial coreceptor that was not present on B cells
(37). The primary data in support of this probability were
that MAb to gH inhibited SVKCR2 infection without influencing the
infection of B cells and that conversion of all two-part gH-gL to
three-part gH-gL-gp42 complexes in virus had the same effect. Addition
of MAb and gp42 were both interpreted as effecting a physical block of
a critical site in gH. The block was in this case obviously not
affecting virus binding, since SVKCR2 cells by virtue of the transfected CR2 receptor can bind virus via gp350. In addition, since
SVKCR2 cells lack the B-cell coreceptor major histocompatibility complex (MHC) class II (10, 16) and can be infected with a virus that lacks gp42 (37), the MHC class II ligand
(32), the existence of a novel epithelial-cell coreceptor
was considered a reasonable possibility. A key question now is whether
the receptor that binds a gH-expressing, but not a virus-lacking gH to
epithelial cells in the absence of CR2 is the same entity as this
postulated coreceptor or is yet another unidentified molecule. Again,
the most straightforward interpretation of the partial blocking of binding by MAbs E1D1 and CL59, both of which also neutralize infection of epithelial cells that express CR2, is that the two receptors are the same.
However, unfortunately, neither the issue of identity of the attachment
protein nor the issue of potential overlap of receptor and coreceptor
can be definitively addressed by antibody studies, with the second of
the two issues perhaps being the most in doubt. Each of the MAbs, which
recognize different epitopes on gH, might affect the conformation of gH
and thus disrupt a distal interactive site just as well as it might
simply block direct access to a binding site by a receptor. By the same
token, an MAb might do both at the same time, that is, block an
interaction with a primary receptor at the epitope to which it binds
and alter conformation elsewhere in the molecule where there is an
interaction with a coreceptor or vice versa. Indeed, if the primary
receptor and the coreceptor are in fact the same molecule, then either
this molecule is expressed at much higher levels on AGS cells than on
cells such as the CR2-negative parent of SVKCR2 cells, SVK, to which
virus binding cannot be visualized with antibody (18), or
the molecule is expressed in an altered form that creates a much higher
affinity for virus. Infection of SVK cells in the absence of
transfected CR2 is not detectable. Infection of the AGS cell line is
considerably less efficient than infection of B cells in that a much
higher concentration of virus is required. However, it is not much less
efficient than infection of SVKCR2 cells, to which virus binds with
high efficiency. Clearly, cloning and sequencing of the receptor and/or
coreceptor are the critical, although by no means trivial, next steps.
The role that epithelial cells play in the normal biology of infection
with EBV has been called into question (35), but there are
several diseases, including nasopharyngeal carcinoma (19),
oral hairy leukoplakia (9), gastric carcinoma
(27), and breast cancer (3), where virus is found
in this cell type. The studies described here suggest that just as EBV
maintains expression of both a three-part gH-gL-gp42 complex that is
essential for infection of B cells and a two-part gH-gL complex that is essential for infection of epithelial cells, so it has one attachment protein, gp350, that binds virus efficiently to B cells via CR2 and a
second attachment protein, probably gH, which can mediate infection of
at least some epithelial cells that lack CR2. Access to the lymphoid
system at mucosal surfaces would certainly be facilitated by at least a
transient infection of mucosal epithelium, and it would appear that the
virus in its evolution as a lymphotropic gammaherpesvirus has at the
least retained or evolved the means with which to effect such an event.
 |
ACKNOWLEDGMENT |
This work was supported by grant AI20662 from the National
Institute of Allergy and Infectious Diseases.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: School of
Biological Sciences, University of Missouri
Kansas City, 5007 Rockhill
Rd., Kansas City, MO 64110-2499. Phone: (816) 235-2575. Fax: (816) 235-5595. E-mail: huttfletcher{at}umkc.edu.
 |
REFERENCES |
| 1.
|
Babic, N.,
B. G. Klupp,
B. Makoschey,
A. Karger,
A. Flamand, and T. C. Mettenleiter.
1996.
Glycoprotein gH of pseudorabies virus is essential for penetration and propagation in cell culture and in the nervous system of mice.
J. Gen. Virol.
77:2277-2285[Abstract/Free Full Text].
|
| 2.
|
Baer, R.,
A. T. Bankier,
M. D. Biggin,
P. L. Deininger,
P. J. Farrell,
T. J. Gibson,
G. Hatfull,
G. S. Hudson,
S. C. Satchwell,
C. Seguin,
P. S. Tuffnell, and B. G. Barrell.
1984.
DNA sequence and expression of the B95-8 Epstein-Barr virus genome.
Nature
310:207-211[CrossRef][Medline].
|
| 3.
|
Bonnet, M.,
J.-M. Guinebretiere,
E. Kremmer,
V. Grunewald,
E. Benhamou,
G. Contesso, and I. Joab.
1999.
Detection of Epstein-Barr virus in invasive breast cancers.
J. Natl. Cancer Inst.
91:1376-1381[Abstract/Free Full Text].
|
| 4.
|
Borza, C., and L. M. Hutt-Fletcher.
1998.
Epstein-Barr virus recombinant lacking expression of glycoprotein gp150 infects B cells normally but is enhanced for infection of the epithelial line SVKCR2.
J. Virol.
72:7577-7582[Abstract/Free Full Text].
|
| 5.
|
Fingeroth, J. D.,
M. E. Diamond,
D. R. Sage,
J. Hayman, and J. L. Yates.
1999.
CD-21 dependent infection of an epithelial cell line, 293, by Epstein-Barr virus.
J. Virol.
73:2115-2125[Abstract/Free Full Text].
|
| 6.
|
Fingeroth, J. D.,
J. J. Weis,
T. F. Tedder,
J. L. Strominger,
P. A. Biro, and D. T. Fearon.
1984.
Epstein-Barr virus receptor of human B lymphocytes is the C3d complement CR2.
Proc. Natl. Acad. Sci. USA
81:4510-4516[Abstract/Free Full Text].
|
| 7.
|
Forrester, A.,
H. Farrell,
G. Wilkinson,
J. Kaye,
N. Davis-Poynter, and T. Minson.
1992.
Construction and properties of a mutant of herpes simplex virus type 1 with glycoprotein H coding sequences deleted.
J. Virol.
66:341-348[Abstract/Free Full Text].
|
| 8.
|
Gardella, T.,
P. Medveczky,
T. Sairenji, and C. Mulder.
1984.
Detection of circular and linear herpesvirus DNA molecules in mammalian cells by gel electrophoresis.
J. Virol.
50:248-254[Abstract/Free Full Text].
|
| 9.
|
Greenspan, J. S.,
D. Greenspan,
E. T. Lennette,
D. I. Abrams,
M. A. Conant,
V. Petersen, and U. K. Freese.
1985.
Replication of Epstein-Barr virus within the epithelial cells of oral "hairy" leukoplakia, an AIDS-associated lesion.
New Engl. J. Med.
313:1564-1571[Abstract].
|
| 10.
|
Haan, K. M.,
W. W. Kwok,
R. Longnecker, and P. Speck.
2000.
Epstein-Barr virus entry utilizing HLA-DP or HLA-DQ as a coreceptor.
J. Virol.
74:2451-2454[Abstract/Free Full Text].
|
| 11.
|
Haddad, R. S., and L. M. Hutt-Fletcher.
1989.
Depletion of glycoprotein gp85 from virosomes made with Epstein-Barr virus proteins abolishes their ability to fuse with virus receptor-bearing cells.
J. Virol.
63:4998-5005[Abstract/Free Full Text].
|
| 12.
|
Heineman, T.,
M. Gong,
J. Sample, and E. Kieff.
1988.
Identification of the Epstein-Barr virus gp85 gene.
J. Virol.
62:1101-1107[Abstract/Free Full Text].
|
| 13.
|
Hoffman, G. J.,
S. G. Lazarowitz, and S. D. Hayward.
1980.
Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen.
Proc. Natl. Acad. Sci. USA
77:2979-2983[Abstract/Free Full Text].
|
| 14.
|
Hurley, E. A., and D. A. Thorley-Lawson.
1988.
B cell activation and the establishment of Epstein-Barr virus latency.
J. Exp. Med.
168:2059-2075[Abstract/Free Full Text].
|
| 15.
|
Imai, S.,
J. Nishikawa, and K. Takada.
1998.
Cell-to-cell contact as an efficient mode of Epstein-Barr virus infection of diverse human epithelial cells.
J. Virol.
72:4371-4378[Abstract/Free Full Text].
|
| 16.
|
Li, Q. X.,
M. K. Spriggs,
S. Kovats,
S. M. Turk,
M. R. Comeau,
B. Nepom, and L. M. Hutt-Fletcher.
1997.
Epstein-Barr virus uses HLA class II as a cofactor for infection of B lymphocytes.
J. Virol.
71:4657-4662[Abstract].
|
| 17.
|
Li, Q. X.,
S. M. Turk, and L. M. Hutt-Fletcher.
1995.
The Epstein-Barr virus (EBV) BZLF2 gene product associates with the gH and gL homologs of EBV and carries an epitope critical to infection of B cells but not of epithelial cells.
J. Virol.
69:3987-3994[Abstract].
|
| 18.
|
Li, Q. X.,
L. S. Young,
G. Niedobitek,
C. W. Dawson,
M. Birkenbach,
F. Wang, and A. B. Rickinson.
1992.
Epstein-Barr virus infection and replication in a human epithelial system.
Nature
356:347-350[CrossRef][Medline].
|
| 19.
|
Liebowitz, D.
1994.
Nasopharyngeal carcinoma: the Epstein-Barr virus association.
Semin. Oncol.
21:376-381[Medline].
|
| 20.
|
Mackett, M.,
M. J. Conway,
J. R. Arrand,
R. S. Haddad, and L. M. Hutt-Fletcher.
1990.
Characterization and expression of a glycoprotein encoded by the Epstein-Barr virus BamHI 1 fragment.
J. Virol.
64:2545-2552[Abstract/Free Full Text].
|
| 21.
|
Meyer, G.,
E. Hanon,
D. Georlette,
P. P. Pastoret, and E. Thiry.
1998.
Bovine herpesvirus type 1 glycoprotein H is essential for penetration and propagation in cell culture.
J. Gen. Virol.
79:1983-1987[Abstract].
|
| 22.
|
Miller, N., and L. M. Hutt-Fletcher.
1988.
A monoclonal antibody to glycoprotein gp85 inhibits fusion but not attachment of Epstein-Barr virus.
J. Virol.
62:2366-2372[Abstract/Free Full Text].
|
| 23.
|
Moore, M. D.,
R. G. DiScipio,
N. R. Cooper, and G. R. Nemerow.
1989.
Hydrodynamic, electron microscopic and ligand binding analysis of the Epstein-Barr virus/C3dg receptor (CR2).
J. Biol. Chem.
34:20576-20582.
|
| 24.
|
Nemerow, G. R.,
C. Mold,
V. Keivens Schwend,
V. Tollefson, and N. R. Cooper.
1987.
Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d.
J. Virol.
61:1416-1420[Abstract/Free Full Text].
|
| 25.
|
Nemerow, G. R.,
R. Wolfert,
M. McNaughton, and N. R. Cooper.
1985.
Identification and characterization of the Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor (CR2).
J. Virol.
55:347-351[Abstract/Free Full Text].
|
| 26.
|
Oba, D. E., and L. M. Hutt-Fletcher.
1988.
Induction of antibodies to the Epstein-Barr virus glycoprotein gp85 with a synthetic peptide corresponding to a sequence in the BXLF2 open reading frame.
J. Virol.
62:1108-1114[Abstract/Free Full Text].
|
| 27.
|
Osato, T., and S. Imai.
1996.
Epstein-Barr virus and gastric carcinoma.
Semin. Cancer Biol.
7:175-182[CrossRef][Medline].
|
| 28.
|
Parker, B. D.,
A. T. Bankier,
S. C. Satchwell,
B. G. Barrell, and P. J. Farrell.
1990.
Sequence and transcription of Raji Epstein-Barr virus DNA spanning the B95-8 deletion region.
Virology
179:339-346[CrossRef][Medline].
|
| 29.
|
Peeters, B.,
N. Dewind,
R. Broer,
A. Gielkins, and R. Moormann.
1992.
Glycoprotein H of pseudorabies virus is essential for entry and cell-to-cell spread of the virus.
J. Virol.
66:3888-3892[Abstract/Free Full Text].
|
| 30.
|
Schroder, C., and G. M. Keil.
1999.
Bovine herpesvirus 1 requires glycoprotein H for infectivity and direct spreading and glycoproteins gH (W450) and gB for glycoprotein D-independent cell-to-cell spread.
J. Gen. Virol.
80:57-61[Abstract].
|
| 31.
|
Shimizu, N.,
H. Yoshiyama, and K. Takada.
1996.
Clonal propagation of Epstein-Barr virus (EBV) recombinants in EBV-negative Akata cells.
J. Virol.
70:7260-7263[Abstract/Free Full Text].
|
| 32.
|
Spriggs, M. K.,
R. J. Armitage,
M. R. Comeau,
L. Strockbine,
T. Farrah,
B. MacDuff,
D. Ulrich,
M. R. Alderson,
J. Mullberg, and J. I. Cohen.
1996.
The extracellular domain of the Epstein-Barr virus BZLF2 protein binds the HLA-DR beta chain and inhibits antigen presentation.
J. Virol.
70:5557-5563[Abstract/Free Full Text].
|
| 33.
|
Takada, K.
1984.
Cross-linking of cell surface immunoglobulin induces Epstein-Barr virus in Burkitt lymphoma lines.
Int. J. Cancer.
33:27-32[Medline].
|
| 34.
|
Tanner, J.,
J. Weis,
D. Fearon,
Y. Whang, and E. Kieff.
1987.
Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping and endocytosis.
Cell
50:203-213[CrossRef][Medline].
|
| 35.
|
Thorley-Lawson, D. A.,
E. M. Miyashita, and G. Khan.
1996.
Epstein-Barr virus and the B cell: that's all it takes.
Trends Microbiol.
4:204-208[CrossRef][Medline].
|
| 36.
|
Wang, X., and L. M. Hutt-Fletcher.
1998.
Epstein-Barr virus lacking glycoprotein gp42 can bind to B cells but is not able to infect.
J. Virol.
72:158-163[Abstract/Free Full Text].
|
| 37.
|
Wang, X.,
W. J. Kenyon,
Q. X. Li,
J. Mullberg, and L. M. Hutt-Fletcher.
1998.
Epstein-Barr virus uses different complexes of glycoproteins gH and gL to infect B lymphocytes and epithelial cells.
J. Virol.
72:5552-5558[Abstract/Free Full Text].
|
| 38.
|
Yaswen, L. R.,
E. B. Stephens,
L. C. Davenport, and L. M. Hutt-Fletcher.
1993.
Epstein-Barr virus glycoprotein gp85 associates with the BKRF2 gene product and is incompletely processed as a recombinant protein.
Virology
195:387-396[CrossRef][Medline].
|
| 39.
|
Yoshiyama, H.,
S. Imai,
N. Shimizu, and K. Takada.
1997.
Epstein-Barr virus infection of human gastric carcinoma cells: implication of the existence of a new virus receptor different from CD21.
J. Virol.
71:5688-5691[Abstract].
|
| 40.
|
Zolotukhin, S.,
M. Potter,
W. W. Hauswirth,
J. Guy, and N. Muzyczka.
1996.
A "humanized" green fluorescent protein cDNA adapted for high-level expression in mammalian cells.
J. Virol.
70:4646-4654[Abstract].
|
Journal of Virology, July 2000, p. 6324-6332, Vol. 74, No. 14
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Young, K. A., Chen, X. S., Holers, V. M., Hannan, J. P.
(2007). Isolating the Epstein-Barr Virus gp350/220 Binding Site on Complement Receptor Type 2 (CR2/CD21). J. Biol. Chem.
282: 36614-36625
[Abstract]
[Full Text]
-
Kirschner, A. N., Lowrey, A. S., Longnecker, R., Jardetzky, T. S.
(2007). Binding-Site Interactions between Epstein-Barr Virus Fusion Proteins gp42 and gH/gL Reveal a Peptide That Inhibits both Epithelial and B-Cell Membrane Fusion. J. Virol.
81: 9216-9229
[Abstract]
[Full Text]
-
Wu, L., Hutt-Fletcher, L. M.
(2007). Compatibility of the gH homologues of Epstein-Barr virus and related lymphocryptoviruses. J. Gen. Virol.
88: 2129-2136
[Abstract]
[Full Text]
-
Hutt-Fletcher, L. M.
(2007). Epstein-Barr Virus Entry. J. Virol.
81: 7825-7832
[Full Text]
-
Fu, D.-X., Tanhehco, Y. C., Chen, J., Foss, C. A., Fox, J. J., Lemas, V., Chong, J.-M., Ambinder, R. F., Pomper, M. G.
(2007). Virus-Associated Tumor Imaging by Induction of Viral Gene Expression. Clin. Cancer Res.
13: 1453-1458
[Abstract]
[Full Text]
-
Guerreiro-Cacais, A. O., Uzunel, M., Levitskaya, J., Levitsky, V.
(2007). Inhibition of Heavy Chain and {beta}2-Microglobulin Synthesis as a Mechanism of Major Histocompatibility Complex Class I Downregulation during Epstein-Barr Virus Replication. J. Virol.
81: 1390-1400
[Abstract]
[Full Text]
-
Gillet, L., May, J. S., Colaco, S., Stevenson, P. G.
(2007). Glycoprotein L Disruption Reveals Two Functional Forms of the Murine Gammaherpesvirus 68 Glycoprotein H. J. Virol.
81: 280-291
[Abstract]
[Full Text]
-
Kirschner, A. N., Omerovic, J., Popov, B., Longnecker, R., Jardetzky, T. S.
(2006). Soluble Epstein-Barr Virus Glycoproteins gH, gL, and gp42 Form a 1:1:1 Stable Complex That Acts Like Soluble gp42 in B-Cell Fusion but Not in Epithelial Cell Fusion. J. Virol.
80: 9444-9454
[Abstract]
[Full Text]
-
Turk, S. M., Jiang, R., Chesnokova, L. S., Hutt-Fletcher, L. M.
(2006). Antibodies to gp350/220 Enhance the Ability of Epstein-Barr Virus To Infect Epithelial Cells. J. Virol.
80: 9628-9633
[Abstract]
[Full Text]
-
Jiang, R., Scott, R. S., Hutt-Fletcher, L. M.
(2006). Epstein-Barr Virus Shed in Saliva Is High in B-Cell-Tropic Glycoprotein gp42. J. Virol.
80: 7281-7283
[Abstract]
[Full Text]
-
Gill, M. B., Gillet, L., Colaco, S., May, J. S., de Lima, B. D., Stevenson, P. G.
(2006). Murine gammaherpesvirus-68 glycoprotein H-glycoprotein L complex is a major target for neutralizing monoclonal antibodies. J. Gen. Virol.
87: 1465-1475
[Abstract]
[Full Text]
-
Shannon-Lowe, C. D., Neuhierl, B., Baldwin, G., Rickinson, A. B., Delecluse, H.-J.
(2006). From the Cover: Resting B cells as a transfer vehicle for Epstein-Barr virus infection of epithelial cells. Proc. Natl. Acad. Sci. USA
103: 7065-7070
[Abstract]
[Full Text]
-
Huang, J., Liao, G., Chen, H., Wu, F. Y., Hutt-Fletcher, L., Hayward, G. S., Hayward, S. D.
(2006). Contribution of C/EBP Proteins to Epstein-Barr Virus Lytic Gene Expression and Replication in Epithelial Cells. J. Virol.
80: 1098-1109
[Abstract]
[Full Text]
-
Omerovic, J., Lev, L., Longnecker, R.
(2005). The Amino Terminus of Epstein-Barr Virus Glycoprotein gH Is Important for Fusion with Epithelial and B Cells. J. Virol.
79: 12408-12415
[Abstract]
[Full Text]
-
Wu, L., Borza, C. M., Hutt-Fletcher, L. M.
(2005). Mutations of Epstein-Barr Virus gH That Are Differentially Able To Support Fusion with B Cells or Epithelial Cells. J. Virol.
79: 10923-10930
[Abstract]
[Full Text]
-
Galdiero, S., Falanga, A., Vitiello, M., Browne, H., Pedone, C., Galdiero, M.
(2005). Fusogenic Domains in Herpes Simplex Virus Type 1 Glycoprotein H. J. Biol. Chem.
280: 28632-28643
[Abstract]
[Full Text]
-
May, J. S., Coleman, H. M., Boname, J. M., Stevenson, P. G.
(2005). Murine gammaherpesvirus-68 ORF28 encodes a non-essential virion glycoprotein. J. Gen. Virol.
86: 919-928
[Abstract]
[Full Text]
-
McShane, M. P., Longnecker, R.
(2004). Cell-surface expression of a mutated Epstein-Barr virus glycoprotein B allows fusion independent of other viral proteins. Proc. Natl. Acad. Sci. USA
101: 17474-17479
[Abstract]
[Full Text]
-
Guerreiro-Cacais, A. O., Li, L., Donati, D., Bejarano, M. T., Morgan, A., Masucci, M. G., Hutt-Fletcher, L., Levitsky, V.
(2004). Capacity of Epstein-Barr virus to infect monocytes and inhibit their development into dendritic cells is affected by the cell type supporting virus replication. J. Gen. Virol.
85: 2767-2778
[Abstract]
[Full Text]
-
Stewart, J. P., Silvia, O. J., Atkin, I. M. D., Hughes, D. J., Ebrahimi, B., Adler, H.
(2004). In Vivo Function of a Gammaherpesvirus Virion Glycoprotein: Influence on B-Cell Infection and Mononucleosis. J. Virol.
78: 10449-10459
[Abstract]
[Full Text]
-
Borza, C. M., Morgan, A. J., Turk, S. M., Hutt-Fletcher, L. M.
(2004). Use of gHgL for Attachment of Epstein-Barr Virus to Epithelial Cells Compromises Infection. J. Virol.
78: 5007-5014
[Abstract]
[Full Text]
-
de Lima, B. D., May, J. S., Stevenson, P. G.
(2004). Murine Gammaherpesvirus 68 Lacking gp150 Shows Defective Virion Release but Establishes Normal Latency In Vivo. J. Virol.
78: 5103-5112
[Abstract]
[Full Text]
-
Farrell, C. J., Lee, J. M., Shin, E.-C., Cebrat, M., Cole, P. A., Hayward, S. D.
(2004). Inhibition of Epstein-Barr virus-induced growth proliferation by a nuclear antigen EBNA2-TAT peptide. Proc. Natl. Acad. Sci. USA
101: 4625-4630
[Abstract]
[Full Text]
-
Isobe, Y., Sugimoto, K., Yang, L., Tamayose, K., Egashira, M., Kaneko, T., Takada, K., Oshimi, K.
(2004). Epstein-Barr Virus Infection of Human Natural Killer Cell Lines and Peripheral Blood Natural Killer Cells. Cancer Res.
64: 2167-2174
[Abstract]
[Full Text]
-
Huang, J., Chen, H., Hutt-Fletcher, L., Ambinder, R. F., Hayward, S. D.
(2003). Lytic Viral Replication as a Contributor to the Detection of Epstein-Barr Virus in Breast Cancer. J. Virol.
77: 13267-13274
[Abstract]
[Full Text]
-
Chen, H., Hutt-Fletcher, L., Cao, L., Hayward, S. D.
(2003). A Positive Autoregulatory Loop of LMP1 Expression and STAT Activation in Epithelial Cells Latently Infected with Epstein-Barr Virus. J. Virol.
77: 4139-4148
[Abstract]
[Full Text]
-
Pasieka, T. J., Maresova, L., Grose, C.
(2003). A Functional YNKI Motif in the Short Cytoplasmic Tail of Varicella-Zoster Virus Glycoprotein gH Mediates Clathrin-Dependent and Antibody-Independent Endocytosis. J. Virol.
77: 4191-4204
[Abstract]
[Full Text]
-
Rasmussen, L., Geissler, A., Cowan, C., Chase, A., Winters, M.
(2002). The Genes Encoding the gCIII Complex of Human Cytomegalovirus Exist in Highly Diverse Combinations in Clinical Isolates. J. Virol.
76: 10841-10848
[Abstract]
[Full Text]
-
Li, L., Liu, D., Hutt-Fletcher, L., Morgan, A., Masucci, M. G., Levitsky, V.
(2002). Epstein-Barr virus inhibits the development of dendritic cells by promoting apoptosis of their monocyte precursors in the presence of granulocyte macrophage-colony-stimulating factor and interleukin-4. Blood
99: 3725-3734
[Abstract]
[Full Text]
-
Rivailler, P., Jiang, H., Cho, Y.-g., Quink, C., Wang, F.
(2002). Complete Nucleotide Sequence of the Rhesus Lymphocryptovirus: Genetic Validation for an Epstein-Barr Virus Animal Model. J. Virol.
76: 421-426
[Abstract]
[Full Text]
-
Maruo, S., Yang, L., Takada, K.
(2001). Roles of Epstein-Barr virus glycoproteins gp350 and gp25 in the infection of human epithelial cells. J. Gen. Virol.
82: 2373-2383
[Abstract]
[Full Text]
-
Haan, K. M., Aiyar, A., Longnecker, R.
(2001). Establishment of Latent Epstein-Barr Virus Infection and Stable Episomal Maintenance in Murine B-Cell Lines. J. Virol.
75: 3016-3020
[Abstract]
[Full Text]
-
Lake, C. M., Hutt-Fletcher, L. M.
(2000). Epstein-Barr Virus That Lacks Glycoprotein gN Is Impaired in Assembly and Infection. J. Virol.
74: 11162-11172
[Abstract]
[Full Text]
-
Janz, A., Oezel, M., Kurzeder, C., Mautner, J., Pich, D., Kost, M., Hammerschmidt, W., Delecluse, H.-J.
(2000). Infectious Epstein-Barr Virus Lacking Major Glycoprotein BLLF1 (gp350/220) Demonstrates the Existence of Additional Viral Ligands. J. Virol.
74: 10142-10152
[Abstract]
[Full Text]